studyfinds1d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
Questions over safety and effectiveness of new Alzheimer's drug
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...
Neuroscience News2d
Alzheimer’s Drug Faces Scrutiny Over Safety, Efficacy Concerns
The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according ...
McKnight's Long-Term Care News1d
Journalists question safety and effectiveness of new Alzheimer’s drug
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
News Medical on MSN1d
Concerns raised over safety and effectiveness of donanemab for Alzheimer’s treatment
The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) ...
BMJ2d
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
Japan approves new drug 'donanemab' to treat Alzheimer's disease
Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.
The i on MSN2d
Alzheimer’s ‘wonder drug’ was approved by scientists funded by pharma firm
A “game-changing” new Alzheimer’s treatment was approved for use in the US by “independent” scientists who had received ...
Alzheimer’s disease could be slowed by boosting a certain protein in the brain, researchers say
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with ...